AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Interleukin-22 receptor subunit alpha-2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q969J5

UPID:

I22R2_HUMAN

Alternative names:

Cytokine receptor class-II member 10; Cytokine receptor family 2 member 10; Cytokine receptor family type 2, soluble 1; Interleukin-22-binding protein; ZcytoR16

Alternative UPACC:

Q969J5; Q08AH7; Q6UWM1; Q96A41; Q96QR0

Background:

Interleukin-22 receptor subunit alpha-2, known by alternative names such as Cytokine receptor class-II member 10 and Interleukin-22-binding protein, plays a pivotal role in the immune response. Isoform 2 acts as a receptor for IL22, inhibiting its interaction with the IL-22R complex and thereby blocking IL22 activity in vitro. This suggests a crucial function in regulating inflammatory responses. Isoform 1 is implicated in the establishment and maintenance of successful pregnancy, highlighting its significance in reproductive health.

Therapeutic significance:

Understanding the role of Interleukin-22 receptor subunit alpha-2 could open doors to potential therapeutic strategies. Its involvement in modulating inflammatory responses and supporting pregnancy suggests avenues for research in treating inflammatory diseases and fertility issues.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.